Volume 23, Issue 9 (September 2025)                   IJRM 2025, 23(9): 749-758 | Back to browse issues page

Ethics code: IR.MUMS.MEDICAL.REC.1400.001


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hatamian Z, Mousavi Vahed S H, Vakilian F, Poorzand H, Lotfalizade M, Zirak N, et al . N-terminal pro-B-type natriuretic peptide levels in pregnant women with heart disease and complications: A cohort study. IJRM 2025; 23 (9) :749-758
URL: http://ijrm.ir/article-1-3152-en.html
1- Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2- Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. , vahedalainh@mums.ac.ir
3- Department of Cardiology, Faculty of Medicine, Lung Diseases Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
4- Department of Cardiology, Faculty of Medicine, Vascular and Endovascular Surgery Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
5- Department of Anesthesiology, Faculty of Medicine, Lung Diseases Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
6- Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
7- Department of Midwifery, Faculty of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:   (51 Views)
Background: Heart diseases affect 1-4% of pregnancies, leading to fetomaternal complications. Brain natriuretic peptide is a key biomarker for assessing cardiac adaptation to pregnancy-related hemodynamic changes. The longer half-life of its terminal fragment, N terminal pro brain natriuretic peptide (NT-ProBNP), increases its diagnostic utility.
Objective: This study aimed to evaluate the association between NT-proBNP serum levels and fetomaternal complications in pregnant women with cardiovascular disease.
Materials and Methods: A prospective longitudinal study was conducted at the Cardiology and Obstetrics Clinic of Imam Reza hospital, Mashhad, Iran, from July 2019-July 2020. 50 pregnant women in their third trimester with cardiovascular disease (New York Heart Association class 2 or higher) were included. Based on NT-proBNP levels, participants were categorized into normal (n = 37) and elevated (n = 13) groups using a 125 pg/ml cutoff. Fetomaternal complications were assessed and analyzed.
Results: Elevated NT-proBNP levels were significantly associated with increased hypertension in the second (p = 0.05) and third (p < 0.0001) visits and low Apgar scores (p = 0.05). A significant difference in drug history (p = 0.013) was observed between the groups. However, no significant differences were found in other variables, including intensive care unit)/neonatal intensive care unit admission, mode of delivery, electrocardiography findings, or echocardiographic results (p > 0.05).
Conclusion: Elevated NT-proBNP levels are strongly linked to hypertension during pregnancy and low neonatal Apgar scores, highlighting its potential as a predictive biomarker for fetomaternal risk assessment.
Type of Study: Original Article | Subject: Pregnancy Health

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb